Holen Sie sich die Stockscreener-App
0.9608
1.79%
-0.0123
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Longeveron Receives Extended Nasdaq Compliance Grace Period - TipRanks
Longeveron Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Longeveron (NASDAQ: LGVN) granted more time to cure Nasdaq $1 bid rule - Stock Titan
Longeveron braces for Q4 results following recent funding boost - MSN
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote - TipRanks
Longeveron (NASDAQ: LGVN) shifts reverse split proposal to annual - Stock Titan
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 earnings call transcript - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Longeveron secures $15M financing with potential for additional $15M tied to trial milestones - MSN
If You Invested $1,000 in Longeveron Inc (LGVN) - Stock Titan
Returns Recap: What are Eureka Acquisition Corps earnings expectationsMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Aug Action: What is Longeveron Incs revenue forecastTrade Volume Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript - Insider Monkey
Longeveron's third-quarter 2026 HLHS trial outcomes may confirm the viability of its overall business approach—while its Alzheimer's program continues to divert focus - Bitget
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure - TipRanks
Longeveron (LGVN) shares surge on $30 million private placement deal - MSN
Longeveron Earnings Call: Pivotal Trials, Tight Cash - TipRanks
Insider Buy: Will Longeveron Inc benefit from rising consumer demand2026 Trading Volume Trends & Growth Oriented Trading Recommendations - baoquankhu1.vn
Treasury Yields: Is Longeveron Inc stock a value trap2026 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
LGVN shares rise after investigational therapy shows improvement in age-related frailty in study - MSN
Longeveron Inc. 2026 10-K: Clinical-Stage Biotech Advancing Laromestrocel (Lomecel-B) for Regenerative Medicine and Intellectual Property Expansion - Minichart
Longeveron Funding & Clinical Strategy: ELPIS II Results Expected Q3 2026News and Statistics - IndexBox
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Longeveron (LGVN) Q4 2025 Earnings Call Transcript - AOL.com
Longeveron Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - BioSpace
Earnings Call Summary | Longeveron(LGVN.US) Q4 2025 Earnings Conference - 富途牛牛
LGVN: $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses - TradingView
Earnings call transcript: Longeveron reports Q4 2025 loss, raises capital By Investing.com - Investing.com South Africa
Earnings call transcript: Longeveron reports Q4 2025 loss, raises capital - Investing.com
LONGEVERON ($LGVN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
LGVN: Revenue fell 50% and net loss rose 41% in 2025, with pivotal HLHS trial results due Q3 2026 - TradingView
LGVN: 2025 net loss widened to $22.7M on lower revenue and higher R&D, with cash needs persisting - TradingView
Longeveron 10-K: Revenues $1.199M, Net Loss $(22.7)M - TradingView
Longeveron Inc. Announces Resignation of Richard Kender from the Board of Directors and Audit Committee, Effective March 2026 - marketscreener.com
Longeveron (NASDAQ: LGVN) advances laromestrocel cell therapy across HLHS and Alzheimer’s - Stock Titan
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
Dividend Watch: Is Privia Health Group Inc stock overvalued or fairly pricedWeekly Investment Report & Community Verified Trade Alerts - baoquankhu1.vn
LGVN Longeveron Inc. (NASDAQ) pre-market 17 Mar 2026: Q4 earnings catalyst - Meyka
Longeveron’s Stem Cell Therapy Boosts Physical Function, Spurs Market Interest - timothysykes.com
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Longeveron Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Longeveron Hits Milestones in Phase 2b Trial and CEO Transition - timothysykes.com
Longeveron Stock on a Rollercoaster: Clinical Trials and CEO Appointment Fuel Market Interest - StocksToTrade
Institutional giants support Longeveron's $30 million fundraising—What makes the HLHS data trigger a major risk-and-reward scenario - Bitget
LGVN Longeveron Inc. (NASDAQ) +20% to $0.97 Mar 13, 2026: earnings, runway - Meyka
Zacks Research Predicts Increased Earnings for Longeveron - Defense World
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):